Table 2 Multivariate analysis
Prostate cancer-specific mortality | Overall mortality | |||
|---|---|---|---|---|
Variable | HR (95% CI) | P | HR (95% CI) | P |
PSA before SADT | 1.0 (1.0–1.0) | 0.06 | 1.0 (1.0–1.0) | 0.06 |
Pre-SADT PSADT <3 months | 4.2 (1.6–11.1) | 0.004 | 2.9 (1.3–6.7) | 0.01 |
DM at SADT initiation | 1.1 (0.4–3.0) | 0.9 | 0.9 (0.4–2.4) | 0.9 |
Undetectable PSA nadir post-SRT | 0.7 (0.2–2.9) | 0.7 | 0.6 (0.2–1.9) | 0.4 |
Total Gleason score | 1.2 (0.7–2.1) | 0.5 | 1.0 (0.6–1.7) | 1.0 |
SVI | 1.7 (0.6–5.1) | 0.3 | 1.8 (0.7–4.6) | 0.2 |
ECE | 0.5 (0.1–2.0) | 0.4 | 0.8 (0.3–2.4) | 0.7 |
SM | 1.5 (0.5–4.6) | 0.5 | 1.0 (0.4–2.7) | 1.0 |
ADT during SRT | 1.1 (0.3–4.2) | 0.9 | 1.6 (0.5–5.1) | 0.4 |
Start date of SRT | 1.0 (1.0–1.0) | 0.4 | 1.0 (1.0–1.0) | 0.1 |
CCMI | 1.2 (0.8–1.9) | 0.4 | 1.0 (0.7–1.5) | 0.8 |
IBF <18 months | 5.8 (1.3–24.1) | 0.02 | 2.7 (0.9–7.9) | 0.07 |